-
For patients with advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with paclitaxel plus cisplatin does not improve progression-free survival or overall survival.
-
Neuropsychiatric Symptoms of Dementia, FDA Actions.
-
Sepilian and Nagamani from the University of Texas in Galveston reported the results of rosiglitazone treatment in 12 obese women with polycystic ovaries and insulin resistance. These women were very heavy, with an average BMI of 40.4. The fasting insulin levels (an average of 46.0 µU) were clearly in the range of hyperinsulinemia due to an increase in insulin resistance.
-
The present study was undertaken to test the hypothesis that high fruit and vegetable consumption reduces the risk of breast cancer. A multinational team of investigators conducted a prospective, observational study of the relationship between fruit and vegetable intake and invasive breast cancer as part of the European Prospective Investigation Into Cancer and Nutrition (EPIC) study.
-
Fecal occult blood tests (FOBTS) were performed on samples from digital rectal examinations in 2665 average-risk asymptomatic adults. In addition, each patient had 6-sample at-home FOBTs done. Colonoscopy was also completed in each subject.
-
-
-
A Crackdown on Importation of Drugs; FDA Actions.
-
Womens Health Initiative (WHI) investigators from Wayne State University performed an analysis using the WHI database and presented the results at the 2004 annual meeting of the American Society of Reproductive Medicine (ASRM). Two months later, the presentation on the effects of oral contraception on cardiovascular disease drew a critical response from the director of the WHI, Barbara Alving, MD, who is also the acting director of the National Heart, Lung, and Blood Institute.
-
Consolidation therapy with oregovomab did not significantly improve TTR overall. A set of confirmatory phase III studies has been initiated to determine whether the SFLT population derives benefit from oregovomab treatment.